Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference

About this update from Nuvectis Pharma, Inc.

Fort Lee, NJ , Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur , Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference . Event H.C. Wainwright Global Investment Conference Date September 9, 2024 Time 12:00 PM ET Link https://journey.ct.events/view/5bacb2fb-d0c8-4efa-92b8-7365c030ddd5 About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study. Company Contact Ron Bentsur Chairman, Chief Executive Officer and President201-614-3151 [email protected] Media Relations Contact Christopher M. Calabrese LifeSci Advisors Tel: 917-680-5608 [email protected] Source: Nuvectis Pharma, Inc.

View stock analysis, news, and events for Nuvectis Pharma, Inc.